CRISPR Therapeutics AGCRSPNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank9
Studio
Year-over-Year Change

Cash generated from core business operations

Latest
$-345.01M
↓ 211% vs avg
Percentile
P9
Near historical low
Streak
1 yr
Consecutive declineContracting
Average
$-110.83M
Historical baseline
PeriodValueYoY Change
2025$-345.01M-141.7%
2024$-142.77M+45.2%
2023$-260.38M+47.5%
2022$-495.74M-192.0%
2021$538.97M+326.1%
2020$-238.37M-520.6%
2019$56.68M+158.9%
2018$-96.24M-37.3%
2017$-70.10M-26.7%
2016$-55.31M-